Abstract
The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
Keywords: Influenza disease, natural compounds, therapeutic targets, drug development, drug repurposing, influenza hemagglutinin inhibitors, influenza NS1 inhibitors, influenza polymerase inhibitors.
Current Pharmaceutical Design
Title:Natural Products as Promising Therapeutics for Treatment of Influenza Disease
Volume: 21 Issue: 38
Author(s): Milan Sencanski, Draginja Radosevic, Vladimir Perovic, Branislava Gemovic, Maja Stanojevic, Nevena Veljkovic and Sanja Glisic
Affiliation:
Keywords: Influenza disease, natural compounds, therapeutic targets, drug development, drug repurposing, influenza hemagglutinin inhibitors, influenza NS1 inhibitors, influenza polymerase inhibitors.
Abstract: The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
Export Options
About this article
Cite this article as:
Sencanski Milan, Radosevic Draginja, Perovic Vladimir, Gemovic Branislava, Stanojevic Maja, Veljkovic Nevena and Glisic Sanja, Natural Products as Promising Therapeutics for Treatment of Influenza Disease, Current Pharmaceutical Design 2015; 21 (38) . https://dx.doi.org/10.2174/1381612821666151002113426
DOI https://dx.doi.org/10.2174/1381612821666151002113426 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Enzymatic Studies in Medicinal Chemistry of Neglected Diseases)
Current Protein & Peptide Science Preface
Endocrine, Metabolic & Immune Disorders - Drug Targets Safety Aspects of Herb Interactions: Current Understanding and Future Prospects
Current Drug Metabolism Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Current Topics in Medicinal Chemistry Targeting Neuropathic Pain: Pathobiology, Current Treatment and Peptidomimetics as a New Therapeutic Opportunity
Current Medicinal Chemistry Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Potential Role of Hydrogen Sulfide in the Pathogenesis of Vascular Dysfunction in Septic Shock
Current Vascular Pharmacology Tackling COVID-19 Through Ayurveda: A Review on the Herbs of Recommended Indian Remedies
Current Traditional Medicine Recent Advances in Pharmaceutical Potential of Brown Algal Polysaccharides and their Derivatives
Current Pharmaceutical Design Internet Resources for Drug Discovery and Design
Current Topics in Medicinal Chemistry Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors
Current Topics in Medicinal Chemistry The Intracellular Mechanism of Berberine-Induced Inhibition of CYP3A4 Activity
Current Pharmaceutical Design Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design Total Synthesis of Cyclosporin O: Exploring the Utility of Bsmoc-NMe- Amino Acid Fluorides and KOAt
Protein & Peptide Letters Diabetic Patients with COVID-19 Complications: Insights into Prevalence, Prognosis, Combination Medications, and Underlying Mechanisms
Current Diabetes Reviews How India Fights with COVID-19 Learning from Highly Affected Countries
Current Signal Transduction Therapy Cinnamaldehyde for the Treatment of Microbial Infections: Evidence Obtained from Experimental Models
Current Medicinal Chemistry Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Prediction of Chemical Multi-target Profiles and Adverse Outcomes with Systems Toxicology
Current Medicinal Chemistry DAMPening Severe COVID-19 with Dexamethasone
Infectious Disorders - Drug Targets